Mumbai, India-based Qure.ai closed a Series D funding round that included an investment by the Merck Global Health Innovation Fund.
The funding will go towards developing foundation models for AI in imaging and expanding Qure.ai’s reach into the U.S. market, the company said. The amount of the investment was undisclosed.
Qure.ai’s products cleared by the U.S. Food and Drug Administration include its qXR-LN chest x-ray lung nodule detection algorithm; qSpot-TB for detecting tuberculosis; and qER-Suite, an AI-enabled head CT tool to expedite the detection, triage, and quantification of traumatic brain injuries and stroke.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
